Lung cancer (NSCLC) — neoantigen vaccine coverage

Clinical

HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T Cells in Subjects With Solid Tumors

Alaunos Therapeutics terminated its screening study (NCT05124743), the data-collection protocol that HLA-typed and somatic-mutation-profiled patients with ovarian/endometrial, colorectal, pancreatic, NSCLC, and cholangiocarcinoma tumors to match them against the company's TCR library as the entry funnel into the TCR001-201 Phase I/II autologous TCR-T study. No therapy was administered under this protocol, and patients without a TCR match were discontinued. Termination closes the screening pipeline that fed the Phase I/II study — a meaningful operational signal for a library-matching approach where match rates gate enrollment.

clinicaltrials · brief 2026-10-15 · published 2026-10-15

Clinical

Investigational Individualized Neoantigen Therapy Clinical Trials for Certain People with Lung Cancer - Black Doctor

The item describes investigational individualized neoantigen therapy clinical trials for certain people with lung cancer, with emphasis on non-small cell lung cancer, which accounts for about 8 in 10 lung cancers, and recurrence after surgery. It also highlights that Black Americans may face later-stage diagnosis and access barriers, making diverse trial representation relevant to neoantigen vaccine development. For investors and industry, the signal is that lung-cancer neoantigen programs must address equity, access, and patient selection, even though the item does not specify a sponsor, trial stage, or outcome.

news · brief 2026-09-26 · published 2026-09-09